Re: Tempostatin in Relation to Liver/GB fibrosis: Possible Cure: Link Dead

August 25, 2005

Tina

Please look at this. It was taken from the " cache " , a snapshot taken by

Google.

The actual page is down. You will see the date is " March 2004 " . If you

do a

search for " Tempostatin " , you will find other pages coming up but they are

dated " 2002 " . For some reason, this most recent page was pulled. Go

figure.

Maybe Tempostatin didn't work out as planned, and the company pulled it.

Or maybe it worked out too well, and the company was given a huge offer to

pull it which they couldn't refuse. Go figure.

This consigns " Tempostatin " to the growing list of medical (not surgical)

treatments

borne out by clinical trials to fight degenerative disease that have been

excitedly

announced in the press and on the Net in recent years, only to

mysteriously vanish

into oblivion a few months or years after their initial announcement.

3040 Ridgewood Road NW

Suite 224

Atlanta, GA 30327

(404) 352-1128

http://www.collgard.com

Report Date: 3/16/2004

Primary Contact

Dr. Bruce Bach

(404) 352-1128

bach@...

Metro Atlanta Chamber of Commerce

Office of Biosciences

235 Young International Blvd.

Atlanta, Georgia 30303

404-586-8443

bio@...

www.AtlantaBioscience.com

Stage

Start-up. Collgard Biopharmaceuticals was founded in 1996. It

is a privately held company that has been conducting clinical trials since 1998.

Summary

Collgard Biopharmaceuticals is a clinical-stage

biotherapeutics company. The company is developing small-molecule drug

treatments that target fibrosis and cancer by directly influencing the tissue

repair process. Combining its understanding of the tissue repair mechanism with

its drug development platform, Collgard is developing breakthrough therapies for

the prevention and treatment of organ failure, bladder cancer, soft tissue

cancers, and fibrosis. The company has current clinical programs in bladder

cancer, dermal fibrosis, and restenosis.

Need Addressed

There are two major classes of diseases which Collgard's lead

drug, Tempostatin, will address: fibrosis and cancer. Fibrosis: The end result

of uncontrolled activation of the tissue repair system. When tissue repair cells

are overstimulated by disease or damage, they fail to repair damage with normal

tissue components. Instead, the repair cells generate a thickened and

structurally simplified patch composed of excess amounts and layers of collagen,

the structural proteins essential for the orderly assembly and maintenance of

tissues and organs. Collgard's drug, Tempostatin, restores the feedback

mechanisms that allow the orderly repair of damaged tissue, and by so doing,

prevent the generation of fibrotic scars. Scar tissue is disorganized and does

not provide the right framework for orderly cell structures. Organ function in

the kidney, liver, and heart depends on the specific arrangement of cells with

specialized functions. Scarring disrupts tissue architecture and prevents cells

from working together properly. Over time, this can lead to organ failure.

Currently there are no effective drugs that inhibit organ scarring or enable

tissue regeneration after damage.

Cancer: The current standard treatment for most cancers

involves radiation, chemotherapy, and surgery. Current therapy is designed to

kill cancer cells but has a negative effect on non-cancer cells. Collgard's

Tempostatin attacks cancer in a novel way. In order to survive and proliferate,

cancer cells depend on stromal cells (a family of connective tissue cells that

have a hand in maintaining the functional integrity of tissues) to provide new

matrix material and blood supply for the tumor's growth. Collgard's Tempostatin

interferes with the interaction between tumor cells and stromal cells, depriving

the cancer cells of the biological infrastructure they depend on to grow and

invade. Some types of tumor cells, when exposed to Tempostatin, will undergo

apoptosis or programmed cell death. Tempostatin's mode of action is to suppress

or eliminate the ability of cancer cells to divide, migrate, and invade.

Tempostatin has shown great promise in animal model studies of bladder cancer,

sarcoma, melanoma, and glioma.

In addition, Tempostatin can be applied to implanted medical

devices. By applying Tempostatin to the surface of a device, it is possible to

inhibit the body's fibrotic reaction to the device and thereby improve the

function and useful lifetime of the device. The first application of Tempostatin

in this area is to prevent restenosis, the re-narrowing of the arteries

post-angioplasty or stent placement. Tempostatin can be applied to the stent

surface and released slowly over time. This helps control the narrowing of blood

vessels due to the vessel's response to injury. Restenosis is a localized form

of tissue scarring.

----- Original Message -----

From: tina83862

gallstones

Sent: Thursday, August 25, 2005 9:01 AM

Subject: another thought

http://www.activeherb.com/qingdan/

I am just throwing stuff out here to see if anyone has used some of

these products.

so if you guys had any luck with anything let me know---tina

August 25, 2005

> Tina

> Please look at this. It was taken from the " cache " , a

snapshot taken by Google.

> The actual page is down. You will see the date is " March

2004 " . If you do a

> search for " Tempostatin " , you will find other pages coming up

but they are

> dated " 2002 " . For some reason, this most recent page was

pulled. Go figure.

> Maybe Tempostatin didn't work out as planned, and the company

pulled it.

> Or maybe it worked out too well, and the company was given a

huge offer to

> pull it which they couldn't refuse. Go figure.

>

> This consigns " Tempostatin " to the growing list of medical

(not surgical) treatments

> borne out by clinical trials to fight degenerative disease

that have been excitedly

> announced in the press and on the Net in recent years, only

to mysteriously vanish

> into oblivion a few months or years after their initial

announcement.

>

> 3040 Ridgewood Road NW

> Suite 224

> Atlanta, GA 30327

> (404) 352-1128

> http://www.collgard.com

> Report Date: 3/16/2004

>

> Primary Contact

>

> Dr. Bruce Bach

> (404) 352-1128

> bach@c...

>

> Metro Atlanta Chamber of Commerce

>

> Office of Biosciences

> 235 Young International Blvd.

> Atlanta, Georgia 30303

> 404-586-8443

> bio@m...

> www.AtlantaBioscience.com

>

> Stage

>

> Start-up. Collgard Biopharmaceuticals was founded

in 1996. It is a privately held company that has been conducting

clinical trials since 1998.

>

> Summary

>

> Collgard Biopharmaceuticals is a clinical-stage

biotherapeutics company. The company is developing small-molecule

drug treatments that target fibrosis and cancer by directly

influencing the tissue repair process. Combining its understanding of

the tissue repair mechanism with its drug development platform,

Collgard is developing breakthrough therapies for the prevention and

treatment of organ failure, bladder cancer, soft tissue cancers, and

fibrosis. The company has current clinical programs in bladder

cancer, dermal fibrosis, and restenosis.

>

> Need Addressed

>

> There are two major classes of diseases which

Collgard's lead drug, Tempostatin, will address: fibrosis and cancer.

Fibrosis: The end result of uncontrolled activation of the tissue

repair system. When tissue repair cells are overstimulated by disease

or damage, they fail to repair damage with normal tissue components.

Instead, the repair cells generate a thickened and structurally

simplified patch composed of excess amounts and layers of collagen,

the structural proteins essential for the orderly assembly and

maintenance of tissues and organs. Collgard's drug, Tempostatin,

restores the feedback mechanisms that allow the orderly repair of

damaged tissue, and by so doing, prevent the generation of fibrotic

scars. Scar tissue is disorganized and does not provide the right

framework for orderly cell structures. Organ function in the kidney,

liver, and heart depends on the specific arrangement of cells with

specialized functions. Scarring disrupts tissue architecture and

prevents cells from working together properly. Over time, this can

lead to organ failure. Currently there are no effective drugs that

inhibit organ scarring or enable tissue regeneration after damage.

>

> Cancer: The current standard treatment for most

cancers involves radiation, chemotherapy, and surgery. Current

therapy is designed to kill cancer cells but has a negative effect on

non-cancer cells. Collgard's Tempostatin attacks cancer in a novel

way. In order to survive and proliferate, cancer cells depend on

stromal cells (a family of connective tissue cells that have a hand

in maintaining the functional integrity of tissues) to provide new

matrix material and blood supply for the tumor's growth. Collgard's

Tempostatin interferes with the interaction between tumor cells and

stromal cells, depriving the cancer cells of the biological

infrastructure they depend on to grow and invade. Some types of tumor

cells, when exposed to Tempostatin, will undergo apoptosis or

programmed cell death. Tempostatin's mode of action is to suppress or

eliminate the ability of cancer cells to divide, migrate, and invade.

Tempostatin has shown great promise in animal model studies of

bladder cancer, sarcoma, melanoma, and glioma.

>

> In addition, Tempostatin can be applied to

implanted medical devices. By applying Tempostatin to the surface of

a device, it is possible to inhibit the body's fibrotic reaction to

the device and thereby improve the function and useful lifetime of

the device. The first application of Tempostatin in this area is to

prevent restenosis, the re-narrowing of the arteries post-angioplasty

or stent placement. Tempostatin can be applied to the stent surface

and released slowly over time. This helps control the narrowing of

blood vessels due to the vessel's response to injury. Restenosis is a

localized form of tissue scarring.

>

> ----- Original Message -----

> From: tina83862

> gallstones

> Sent: Thursday, August 25, 2005 9:01 AM

> Subject: another thought

>

> http://www.activeherb.com/qingdan/

>

> I am just throwing stuff out here to see if anyone has used some

of

> these products.

>

> so if you guys had any luck with anything let me know---tina

>

August 25, 2005